Screener
Theravance Biopharma TBPH Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $219,766 | $167,806 |
| Short-term marketable securities | 167,891 | 147,551 |
| Receivables from collaborative arrangements | 20,381 | 45,539 |
| Receivables from milestones and royalty assets | — | 50,000 |
| Other prepaid and current assets | 8,624 | 7,564 |
| Total current assets | 416,662 | 418,460 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's short-term investments?
- Theravance Biopharma (TBPH) reported short-term investments of $167.89M in Q2 2026.
- How has Theravance Biopharma's short-term investments changed year-over-year?
- Theravance Biopharma's short-term investments increased by 195.2% year-over-year, from $56.88M to $167.89M.
- What is the long-term trend for Theravance Biopharma's short-term investments?
- Over 5 years (2020 to 2025), Theravance Biopharma's short-term investments has grown at a -6.9% compound annual growth rate (CAGR), from $211.47M to $147.55M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Theravance Biopharma's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude